Methylprednisolone. Within two days, his diarrhea was signifi cantly improved. He was switched to oral Prednisone upon discharge. Two weeks post-discharge, the patient was doing well, with complete resolution of his diarrhea, having one formed bowel movement daily. Conclusion: Multiple chemotherapy agents and monoclonal antibodies, such as Ipilimumab, have been shown to cause diarrhea, and rarely lead to colitis. Drug-induced colitis should always be part of the differential for patients undergoing any form of chemotherapy presenting with diarrhea or blood in stool. If colitis is secondary to Ipilimumab, prompt discontinuation of treatment with initiation of corticosteroids may quickly reverse the active colitis, limit morbidity and improve quality of life.
Purpose: A 43-year-old man presents with eight days of right-sided abdominal pain and constipation without fever or emesis. Th e pain is sharp, non-radiating, colicky, and only alleviated by bowel movements. At baseline, he has three bowel movements daily. However, this has decreased to once daily over the past week, with none on the day of presentation. His history is signifi cant for AIDS, Clostridium diffi cile colitis, and Hodgkin's lymphoma, for which he received treatment one week prior with vinblastine, bleomycin, dacarbazine, and doxorubicin. Home medications include ARV therapy and oxycodone-acetaminophen. On presentation, he was afebrile with stable vital signs. Abdominal exam revealed mild abdominal distention and diff use abdominal tenderness, most pronounced in the right upper and lower quadrants. CBC showed pancytopenia. CT was remarkable for copious stool in the colon and mild thickening of the cecal wall with surrounding infl ammatory change. Th e patient was started on a bowel regimen. He had a large formed bowel movement three days aft er admission, with concomitant improvement of his abdominal pain and distention. Stool studies revealed C. diffi cile toxin B gene by PCR, with a confi rmed negative one month prior to presentation. He was diagnosed with recurrent C. diffi cile infection (CDI) and treated with metronidazole for 14 days. CDI has increased in incidence and severity over the last decade. Risk factors include antibiotic use, gastric acid suppression, advanced age, and severe illness. Epidemiological studies consistently show that immunocompromised patients are at increased risk for CDI. Frequent hospitalization and use of antibiotics augment risk amongst this cohort. Case series suggest some chemotherapeutic agents (e.g. doxorubicin) are also independent risk factors for development of CDI. CDI is classically defi ned by acute diarrhea with confi rmed C. diffi cile toxin. It is oft en associated with fever, lower abdominal pain, tenesmus, and leukocytosis. Abdominal CT may show diff use colonic wall thickening. Rarely does CDI present with constipation unless complicated by toxic megacolon. Clinical presentation of CDI in immunosuppressed patients undergoing chemotherapy may be atypical. Features may include right-sided abdominal pain, constipation, and distention, although these symptoms are more typical of typhlitis. Th is patient had several risk factors for CDI, including history of CDI, AIDS, and recent chemotherapy, but his presentation fi t an atypical profi le for CDI. Opiates likely contributed to his constipation. In patients who have multiple risk factors for C. diffi cile infection, there should be high clinical suspicion for infection, despite an atypical presentation.
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A Crystal in Ulcer
Varun Gaur, MD, 1 Mazen Albeldawi, MD, 2 Luke Weber, MD 2 . 1. Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH; 2. Cleveland Clinic Foundation, Gastroenterology, Cleveland, OH. Purpose: A 61-year-old male presented to the ER complaining of fatigue, dizziness, and BRBPR for two days. Past medical history is signifi cant for GERD, Hep C, GIB secondary to NSAID-induced gastric ulcer, and ESRD s/p two failed renal graft s. Current medications include pantoprazole, sevelamer, kayexalate, senna, and metoprolol. On admission, the patient was found to be hypotensive with a hemoglobin (Hb) of 9 g/dl (baseline 10-11 g/dl). His blood pressure responded appropriately to fl uid resuscitation. Subsequent EGD revealed a single non-bleeding gastric ulcer (3 mm) in the pre-pyloric region of the stomach with no stigmata of bleeding. Th e patient continued to have intermittent episodes of BRBPR, necessitating multiple blood transfusions, and a colonoscopy was done, revealing evidence of colitis and localized ulcerations in the proximal ascending colon and cecum status post biopsies. During the hospitalization, an angiography was also performed, which revealed active bleeding from cecal branches of ileocolic artery status post embolization with cessation of bleeding. Biopsy results from the cecal ulcers on colonoscopy revealed single particle of crystalline material in the background of an ulcer consistent with kayexalate-induced ulcers (Image 1). Many drugs can cause non-specifi c damage in the large intestine, including solitary hemorrhages, erosions, ulcers, and infl ammation. Th e pathogenesis of the lesions caused by drugs is highly variable, with toxic injury and vascular insuffi ciency thought to be the most common. Kayexalate-induced intestinal injury reveals rhomboid or triangular basophilic crystals adherent to surface epithelium. Kayexalate is a cation exchange resin which acts in the large intestine by exchanging sodium ions for potassium ions. Th e mechanism of mucosal damage is not clear, and is reported to be more common in patients with renal failure. It is speculated to be caused by its osmotic action and vasospasm of intestinal vasculature. Th e patient in this case recovered aft er discontinuation of kayexalate. Th is case highlights the importance of medication-induced GI tract injury. Physicians should be aware of colonic ulceration and ischemia in renal failure patients taking kayexalate. Purpose: To describe clinical usage of retinyl palmitate suppositories for the treatment of severe formalin colitis. Description: An 80-year-old male developed chronic radiation proctopathy (CRP) aft er receiving external beam radiation for prostate cancer. Th is was characterized by periodic rectal bleeding that did not respond to 5-aminosalicylic acid suppositories or short-chain fatty acid enemas. Rectal instillation of formalin was performed under general anesthesia using two aliquots of 100 and 200 ml of unknown concentration with three-minute contact time for each instillation, followed by removal with irrigation and suctioning. Formalin instillation was immediately followed by hospitalization for fever and abdominal pain, requiring IV fl uids and antibiotics. Sigmoidoscopy revealed diff use severe infl ammation of the rectum and sigmoid colon (Figure 1) . A subsequent perforation occurred and was managed conservatively during a prolonged hospitalization. Despite 50 hyperbaric oxygen sessions and a laparoscopic diverting loop ileostomy, the patient continued to have debilitating rectal pain and tenesmus. He received retinyl palmitate suppositories 20,000 IU daily as part of an open-label study of this treatment for CRP. He had resolution of all symptoms with a decrease in Radiation Proctopathy Symptom Assessment Score from 21 to six. Sigmoidoscopy performed aft er 90 days of therapy revealed only mild colonic infl ammation (Figure 2 ). No adverse events or change in serum vitamin A occurred during the trial. He has since undergone ileostomy closure and has remained symptom-free on daily suppository treatment. Retinyl palmitate suppositories represent a useful, well-tolerated therapy for formalin colitis.
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[1274] Cecal ulcer biopsy.
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Disseminated Histoplasmosis Involving the Colon and Omentum: A Rare Presentation in the Setting of Immunomodulator Th erapy
Matthew Soape, MD, 1 Ryan Romano, MD, 2 Seshadri Th irumala, MD, 3 Elias Ghandour, MD 3 . 1. Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX; 2. Mayo Clinic, Rochester, MN; 3. Covanent Hospital, Lubbock, TX. Purpose: First described in 1906, histoplasmosis is caused by Histoplasma capsulatum (H. capsulatum) . Usually a self-limiting pulmonary infection, it is the most prevalent mycotic infection in the US. However, one in 2,000 active infections can become disseminated. We present a case of disseminated histoplasmosis (DI) involving the colon and omentum, mimicking a primary mass lesion with peritoneal spread. Case Report: A 59-year-old male presented with abdominal pain, diarrhea and signifi cant weight loss. His past medical history included rheumatoid arthritis (RA). Medications included Remicade and methotrexate. As a truck driver, he traveled within Texas, New Mexico and Oklahoma. A computed tomography scan of the abdomen showed diff use omentum caking with masses in the transverse colon (Fig1A). Colonoscopy revealed a near obstructing, malignant-appearing mass in the colon (Fig1B) . Biopsies of the mass and omentum were initially non-diagnostic. A surgical consult was obtained, and he underwent a loop ileostomy with concern of GI obstruction. Secondary review of the histologic sections by an outside facility revealed hyphae and yeast with narrow-based budding consistent with H. capsulatum (Fig1C,D) . He was treated with IV amphotericin B for two weeks and oral intraconazole for six additional weeks. His ileostomy was later reversed with no complications. Discussion: Although largely asymptomatic, H. capsulatum can aff ect the lungs through inhalation of hyphal fragments. Most infections follow exposure to bird or bat droppings. It is mostly isolated to endemic areas of the Ohio and Mississippi River valleys and East Coast. Interestingly, our patient had not traveled to these areas or have any exposure to birds. DI is a rare infection, and usually occurs with immuno compromised patients. Risk factors include extreme ages, AIDS and immunosuppressive medications. IL-12 works to increase the activity of IFN-γ and TNF-α with resultant destruction of the H. capsulatum organisms. Remicade (infl iximab), a TNF-α antibody with inhibitory activity, most likely contributed to his disease. Our case highlights an extremely rare presentation of disseminated histoplasmosis mimicking a gastrointestinal malignancy and its potential association with immunomodulator therapy.
